Skip to Content

Swedish Orphan Biovitrum AB SOBI

Morningstar Rating
SEK 280.20 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Sobi Earnings: Maintaining Our SEK 252 Valuation Following Particularly Strong First Quarter

Sobi’s top line grew 19% in a particularly strong first quarter, and we’re maintaining our SEK 252 fair value estimate. Management maintained its full-year forecast for high-single-digit revenue growth at constant exchange rates and an adjusted EBITA margin in the mid-30s, and we think the firm looks on track to maintain this level of growth and EBITA margin for the next several years. However, we do not assign Sobi a moat, given competitive pressures in the hemophilia market and Sobi’s lack of internal innovation to support its intangible assets beyond our 10-year explicit forecast.

Price vs Fair Value

SOBI is trading at a 120% premium.
Price
SEK 280.20
Fair Value
SEK 878.00
Uncertainty
High
1-Star Price
SEK 179.30
5-Star Price
SEK 575.20
Economic Moat
Llr
Capital Allocation
Bzvfccjf

Bulls Say, Bears Say

Bulls

Sobi’s Elocta was first-to-market in Europe among EHL treatments in hemophilia A, and Sobi's potential launch of once-weekly Altuviiio in 2024 in Europe should extend the firm's franchise despite competition.

Bears

With a growing number of hemophilia A and B competitors (EHL therapies, subcutaneous options, and gene therapy), Sobi could have a difficult time recruiting new patients and maintaining pricing.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SOBI is a good fit for your portfolio.

News

Trading Information

Previous Close Price
SEK 280.20
Day Range
SEK 278.40281.60
52-Week Range
SEK 189.03302.00
Bid/Ask
SEK 279.00 / SEK 279.40
Market Cap
SEK 95.23 Bil
Volume/Avg
143,693 / 453,539

Key Statistics

Price/Earnings (Normalized)
36.67
Price/Sales
4.01
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Growth
Total Number of Employees
1,752

Competitors

Valuation

Metric
SOBI
4502
ALNY
Price/Earnings (Normalized)
36.6715.66
Price/Book Value
2.640.89
Price/Sales
4.011.539.37
Price/Cash Flow
16.657.4987.88
Price/Earnings
SOBI
4502
ALNY

Financial Strength

Metric
SOBI
4502
ALNY
Quick Ratio
0.500.462.86
Current Ratio
0.711.063.08
Interest Coverage
3.101.93−3.36
Quick Ratio
SOBI
4502
ALNY

Profitability

Metric
SOBI
4502
ALNY
Return on Assets (Normalized)
3.69%2.86%−2.47%
Return on Equity (Normalized)
8.14%6.13%
Return on Invested Capital (Normalized)
7.02%4.78%−7.00%
Return on Assets
SOBI
4502
ALNY
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
MKKGY
Merck KGaA ADRHysssskmnGzmnnb$78.2 Bil
ZTS
Zoetis Inc Class AWdcpwkytWws$78.0 Bil
HLN
Haleon PLC ADRFnmyzgqcGypfc$38.2 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRTsfwrhzwsShsz$19.1 Bil
VTRS
Viatris IncCdkwjsntzWkfsx$12.5 Bil
RDY
Dr Reddy's Laboratories Ltd ADRLyzvjllMndnz$11.8 Bil
CTLT
Catalent IncNcffmbsvTmrvhy$9.9 Bil
PRGO
Perrigo Co PLCFtthmjkwfLjbhs$3.8 Bil
CURLF
Curaleaf Holdings IncRhvppfbJhxdf$3.5 Bil
PBH
Prestige Consumer Healthcare IncJrmphrrWmzvdc$3.2 Bil

Sponsor Center